PF-07826390

N/A

Report date: 2025/11/07 20:01:05

Base Information

Drug NamePF-07826390
Drug Alias NamePF-07826390
ClassificationBiologics
Mechanisms of ActionLeukocyte immunoglobulin-like receptor B1 inhibitorsLeukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors
TargetsLeukocyte immunoglobulin-like receptor B1Leukocyte immunoglobulin-like receptor subfamily B member 2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsSquamous Cell Carcinoma of Head and Neck +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsSquamous Cell Carcinoma of Head and Neck +[6] 

Other Information

ATC CodeN/A
Related LinksN/A